Program
JAR-2203
A development code.
Its studies are mostly in Hyperlipoproteinemias, led by Beijing Jiake Ruikang Pharmaceutical Technology.
Furthest: phase 1, since Nov 8, 20261 company-led study, 1 open or runningNext primary completion: Jul 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Jiake Ruikang Pharmaceutical Technology | 11 open or running | phase 1since Nov 8, 2026 | Nov 8, 2026 | Jul 30, 2027phase 1 · NCT07937254 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 8, 2026First study: phase 1 study in Lipid Metabolism DisordersFirst studyNCT07937254 · 44 planned · China
Ahead
- Jul 30, 2027Primary completion: phase 1 study in Lipid Metabolism DisordersNCT07937254
TargetBeta
LPA →read by rule
“JAR-2203 is an investigational small interfering RNA (siRNA) targeting LPA mRNA to reduce plasma lipoprotein(a) \[Lp(a)\] levels.”study text, by rule · the study
Other programs on LPA
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07937254Lipid Metabolism Disorders · China | 1 | Recruiting | Jul 30, 2027 | 44 |
How it is read
Names in the registry
- “JAR-2203”, 1 entry
Codes read as this program: JAR2203.
Conditions, from the studies’ own filings
- Hyperlipoproteinemias, 1 study
First seen by our ledger Nov 17, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.